MaximeDelforge

[The Lancet @TheLancet]

Oncolytic viruses have the unique ability to selectively replicate within (and to destroy) cancer cells, offering a promising approach in cancer treatment.

A new Review summarises clinical progress, remaining challenges, & future research directions: https://t.co/j7WZWrAHEf

[Mostafa Faisal @MostafaFaisal14]

Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma @LeukemiaJnl https://t.co/hN63JWf5PE

[Mohamad Mohty @Mohty_EBMT]

The paper of the day: a landmark publication that is bound to serve as a reference for years to come!
⁦@NatRevClinOncol⁩ ⁦@thanosdimop⁩ ⁦@COMyCongress⁩ ⁦@TheIACH⁩ ⁦@mbeksac56⁩ ⁦

[Benlazar S M A @smbenlazar]

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management https://t.co/CZjw2wDeRy #AML #leusm

[Lymphoma Hub @lymphomahub]

The initial results from the LOTIS-7 study on the combination of loncastuximab tesirine plus glofitamab for R/R #DLBCL were presented at #18ICML

Watch the full video featuring @JuanAlderuccio here: https://t.co/LNNWJAkiJ9

#lymphoma #lymsm

[Eddie Cliff @Eddie_Cliff]

Impressive data in the challenging-to-treat Richter’s transformation population with Ven+R-CHOP with 50% PFS at 15 months #18ICML #lymsm

[Graham Collins @graham74GC]

Wurm-Kuczera: R-pola-glo in unfit 1L DLBCL. Anthacycline ineligible ‘Ix discretion’
• glofit, pola, ritux. Fixed duration
• EOT: 90% ORR & 81% CMR
• 4% ICANs, G3+ CRS 2.5%
V impressive responses. Need to see survival endpoints.
#18ICML #ICML25 #lymsm

[Lymphoma Hub @lymphomahub]

CONGRESS | #18ICML | PRESENTATION
Michael Wang @michaelwangmd @MDAndersonNews discusses results from the SYMPATICO study of first-line ibrutinib plus venetoclax in patients with #MantleCellLymphoma who are ≥65 years or have TP53 mutations; concluding that this combination may be feasible in older patients and patients of any age with a TP53 mutation.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedEd #MedNews

[Nico Gagelmann @NicoGagelmann]

Nivo-AVD is the new R-CHOP for Hodgkin's

⁦@JCO_ASCO⁩ https://t.co/tRHG5MspLh

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2025 | PRESENTATION
Arnon P. Kater @arnon_kater @amsterdamumc shares the final analysis from the phase III GAIA/CLL13 trial, which compared three different time-limited venetoclax-based combinations against chemoimmunotherapy.
With more than 5 years of follow-up, venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy. No differences in OS were observed between treatment arms.
In addition to PFS, factors such as tolerability, QoL, and OS should be considered when considering adding ibrutinib to venetoclax-obinutuzumab.
Follow our live feed for more updates: https://t.co/MxLvGStEvp
#lymphoma #lymsm #leusm #MedicalCongress

[Toby Eyre @tobyeyre82]

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 | Journal of Clinical Oncology https://t.co/wopz4ldUI6

[Vincent Rajkumar @VincentRK]

Key Myeloma therapy update for 2025

1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd).

2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk.

4) Use new IMWG IMS risk stratification

5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction).

6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2025 | PRESENTATION
Matthew Matasar @DrMatasar @RutgersCancer presents results from the phase III POLARGO trial assessing Pola-R-GemOX for transplant-ineligible patients with R/R DLBCL (N = 255).
Pola-R-GemOx demonstrated improved OS and PFS outcomes, with a 40% reduction in risk of death relative to R-GemOx. These results highlight the benefit of combining polatuzumab vedotin with chemotherapy treatment for patients with DLBCL.
Follow our live feed for more updates: https://t.co/Pgr10wSsK3
#lymphoma #lymsm #MedicalCongress

[Mohamad Mohty @Mohty_EBMT]

Practice-changing results
Congratulations to authors and contributors
@TheIACH

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2025 | PRESENTATION
Martin Dreyling, Klinikum der Universitaet Munchen highlights an analysis of high-risk patients with treatment-naïve MCL who were treated with rituximab-bendamustine (BR) with or without acalabrutinib in the phase III ECHO trial.
Acalabrutinib + BR improved PFS vs placebo + BR in patients with high-risk MCL. Outcomes in patients with high-risk disease align with results from the overall study population.
Follow our live feed for more updates: https://t.co/Pgr10wSsK3
#lymphoma #lymsm #MedicalCongress

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2025 | PRESENTATION
Marek Trneny @MarekTrnenyDr @CharlesUniPRG presents results from the phase III inMIND trial assessing tafasitamab in combination with lenalidomide and rituximab in patients with R/R FL or MZL.
The addition of tafasitamab to Len + R resulted in significant and clinically meaningful improvement in PFS in patients with R/R FL, with a benefit observed across all prespecified subgroups. The safety profile was manageable and consistent with expected toxicities. Tafasitamab in combination with Len + R may represent a new standard of care for patients with R/R FL.
Follow our live feed for more updates: https://t.co/Pgr10wSsK3
#lymphoma #lymsm #MedicalCongress

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm @JCO_ASCO New definition of high risk multiple myeloma by IMWG

➡️https://t.co/1q0Gldh7Rs

Summary 👇

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO25 | @HangQuach1 @UniMelb shares initial results from part 1 of the MagnetisMM-6 study of elranatamab + DR for patients with transplant-ineligible newly diagnosed #MultipleMyeloma. Elranatamab 76mg Q4W + standard dose DR demonstrated ORR of 97.3% with a predictable safety profile, consistent with the known safety profile of the individual agents.
Follow our live feed for more updates: https://t.co/aicU0GaR8Q
#mmsm #myeloma #MedicalCongress

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO25 | Heather Jolie Landau @MSKCancerCenter shares safety and efficacy data from the phase Ib/II NEXICART-2 study of NXC-201 for R/R AL #amyloidosis. 70% of patients experienced hematologic CR, all CRS were low grade and there were no incidence of neurotoxicity. At a median FU of 131 days, there were no hematologic relapse or progression observed.
Follow our live feed for more updates: https://t.co/aicU0GboYo
#mmsm #myeloma #MedicalCongress

[Nico Gagelmann @NicoGagelmann]

🎉Finally out🎉

Our study showed value of low dose splenic irradiation and transplantation as part of a curative approach in myelofibrosis with refractory splenomegaly:
- significant spleen size reduction
- excellent engraftment

#mpnsm @ASTCT_Journal
https://t.co/Yk6K8qW7il